Stockreport

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

Kairos Pharma, Ltd.  (KAPA) 
PDF The next-generation, AI-designed pan-EGFR inhibitor for EGFR-mutant lung cancer significantly expands the Company’s oncology pipeline Targeting a $16.2 Billion Market Op [Read more]